AVE9633 / ImmunoGen, AbbVie, Sanofi  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
AVE9633 / Sanofi
NCT00543972: Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia

Terminated
1
12
US, Europe
AVE9633
Sanofi
Myeloid Leukemia
08/08
08/08

Download Options